ThursdayJul 21, 2011 10:28 am
Yesterday, Neoprobe Corp. announced that it has formed a European business unit. This unit solidifies Neoprobe's expanding focus in the areas of radiopharmaceuticals and lymphatic mapping that are occurring in Europe, which will play an important part in Neoprobe's Lymphoseek products and technology. Neoprobe is a biomedical company that focuses on improving the oncology patient care process via radiopharmaceutical products. Currently, Neoprobe is developing two different radiopharmaceutical platforms, Lymphoseek and RIGScan. Lymphoseek is a radioactive diagnostic tracing agent for use in surgical gamma detection devices. Part of Neoprobe's European strategy is to create business partnerships with partners capable of providing…
Continue Reading